Abstract
In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011–2016 cohort. After initiation of treatment, the median decrease in the number of patients per each subsequent line of therapy was 22%. Lenalidomide-dexamethasone (n = 156), bortezomib-dexamethasone (n = 107), and bortezomib-lenalidomide-dexamethasone (n = 84) were the most commonly used regimens. The partial response or better rate was 78%, 58%, 55%, and 44% in lines of therapy one to four, respectively. The median (95% confidence interval [CI]) progression-free survival was 18 (15–22), 10 (8–13), 8 (7–10), and 6 (4–8) months in lines of therapy one to four, respectively. The median (95% CI) overall survival (OS) was 4.1 (3.7–4.8) years. Compared with the 2006–2010 cohort, patients in the 2011– 2016 cohort had longer OS; 5.3 (4.7 to not reached) versus 3.4 (2.7–4.0) years, p < 0.0001. This was especially true in patients not treated with high-dose therapy and autologous stem cell transplantation; 4.7 (3.2–5.9) versus 2.6 (2.0–3.3) years, p = 0.0052. Patients in the 2011–2016 cohort were on treatment during a greater part of their life and had higher exposure to high-dose melphalan with autologous stem cell transplantation, lenalidomide, pomalidomide, daratumumab, and carfilzomib.
Article PDF
Avoid common mistakes on your manuscript.
References
Rajkumar, SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91;719–34.
Blimark, C, Holmberg, E, Mellqvist, U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015;100;107–13.
Thorsteinsdottir, S, Dickman, PW, Landgren, O, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 2018;103;e412–e15.
Bladé, J, San Miguel, JF, Fontanillas, M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 1996;14;2167–73.
Harousseau, JL, Attal, M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997;34;61–6.
Barlogie, B, Jagannath, S, Vesole, DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89;789–93.
Kumar, SK, Rajkumar, SV, Dispenzieri, A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111;2516–20.
Kumar, SK, Dispenzieri, A, Lacy, MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28;1122–8.
Kazandjian, D, Landgren, O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol 2016;43;682–9.
Moreau, P. How I treat myeloma with new agents. Blood 2017; 130;1507–13.
Klausen, TW, Gregersen, H, Abildgaard, N, et al. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia 2019;33;546–9.
Moreau, P, San Miguel, J, Sonneveld, P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28;iv52–iv61.
Nijhof, IS, van de Donk, NWCJ, Zweegman, S, Lokhorst, HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs 2018;78;19–37.
Moreau, P, Zamagni, E, Mateos, M-V. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J 2019;9;38.
Sonneveld, P, Broijl, A. Treatment of relapsed and refractory multiple myeloma. Haematologica 2016;101;396–406.
Nooka, AK, Kastritis, E, Dimopoulos, MA, Lonial, S. Treatment options for relapsed and refractory multiple myeloma. Blood 2015;125;3085–99.
Kumar, SK, Lee, JH, Lahuerta, JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26;149–57.
Yong, K, Delforge, M, Driessen, C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016;175;252–64.
Raab, MS, Cavo,M, Delforge, M,et al. Multiple myeloma: practice patterns across Europe. Br J Haematol 2016;175;66–76.
Kumar, SK, Dimopoulos, MA, Kastritis, E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 2017;31;2443–8.
Mohty, M, Terpos, E, Mateos, M-V, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective,multinational, noninterventional study. Clin Lymphoma Myeloma Leuk 2018;18;e401–e19.
Gengenbach, L, Reinhardt, H, Ihorst, G, et al. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials Leuk. Lymphoma 2018;59;2692–9.
Rajkumar, SV. Updated diagnostic criteria and staging system for multiple myeloma.Am Soc Clin Oncol Educ B 2016;35;e418–e23.
Gimsing, P, Holmstrøm, M, Wirenfelt Klausen, T, et al. The Danish national multiple myeloma registry. Clin Epidemiol 2016; 8;583–7.
Rajkumar, SV, Richardson, P, San Miguel, JF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood 2015;126;921–2.
Rajkumar, SV, Harousseau, J-L, Durie, B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma workshop consensus panel 1. Blood 2011;117;4691–5.
Andersen, KT, Hinge, M, Segel, E, et al. Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. Clin Lymphoma Myeloma Leuk 2015;15;e144.
Hinge, M, Andersen, KT, Lund, T, et al. Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment. Haematologica 2016;101;e419–e22.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology
Data availability statement: Raw data were generated at Open Patient data Exploratory Network. Derived data supporting the findings of this study are available from the corresponding author (AGS) on request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Szabo, A.G., Iversen, K.F., Möller, S. et al. The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study. Clin Hematol Int 1, 220–228 (2019). https://doi.org/10.2991/chi.d.190805.002
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190805.002